Evidence map›Paper›PMID 35765042›Full record

ArticleBMC pediatrics2022

Analysis of 4 cases of children with false-positive results of novel coronavirus-specific antibody.

Shuzhi Dai, Jingjing Li, Jing Li, Long Li, Lin Shi, Ling Cao, Xuemei Zhong, Weijie Liu, Ying Wang, Lijuan Ma

Open access · goldAbstract read
In one paragraph

Article in BMC pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Shuzhi DaiDepartment of Clinical Laboratory, Children's Hospital, Capital Institute of Pediatrics, No.2 Yabao Road, Chaoyang District, Beijing, 100020, China.
Jingjing LiDepartment of Clinical Laboratory, Children's Hospital, Capital Institute of Pediatrics, No.2 Yabao Road, Chaoyang District, Beijing, 100020, China.
Jing LiDepartment of Clinical Laboratory, Children's Hospital, Capital Institute of Pediatrics, No.2 Yabao Road, Chaoyang District, Beijing, 100020, China.
Long LiDepartment of General Surgery, Children's Hospital, Capital Institute of Pediatrics, Beijing, China.
Lin ShiDepartment of Cardiovascular Medicine, Children's Hospital, Capital Institute of Pediatrics, Beijing, China.
Ling CaoDepartment of Respiration, Children's Hospital, Capital Institute of Pediatrics, Beijing, China.
Xuemei ZhongDepartment of Gastroenterology, Children's Hospital, Capital Institute of Pediatrics, Beijing, China.
Weijie LiuDepartment of Clinical Laboratory, Children's Hospital, Capital Institute of Pediatrics, No.2 Yabao Road, Chaoyang District, Beijing, 100020, China.
Ying WangDepartment of Clinical Laboratory, Children's Hospital, Capital Institute of Pediatrics, No.2 Yabao Road, Chaoyang District, Beijing, 100020, China.
Lijuan MaDepartment of Clinical Laboratory, Children's Hospital, Capital Institute of Pediatrics, No.2 Yabao Road, Chaoyang District, Beijing, 100020, China. malijuan@shouer.com.cn.
Children's Hospital of Capital Institute of Pediatrics · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study attempts to explore the influencing factors and solutions of the colloidal gold method for novel coronavirus (2019-nCoV)-specific IgM/IgG antibody detection, summarize the clinical experience and perfect the examination process, improving the application value of antibody detection in COVID-19 diagnosis.

methodsA total of 13,329 peripheral whole blood/plasma/serum samples were obtained for COVID-19 screening from children who visited the Children's Hospital of the Capital Institute of Pediatrics outpatient clinic from April 22, 2020, to November 30, 2020. The colloidal gold method was adopted for 2019-nCoV-specific IgM/IgG antibody detection. The virus nucleic acid test results, clinical records, and serum protein fingerprint results of antibody-positive patients were collected.

resultsAll samples were examined using the colloidal gold method with two 2019-nCoV-specific IgM/IgG antibody detection kits. Four patients were tested single antibody-positive using both kits. The details were as follows: two cases of IgM ( +) and IgG (-) using plasma and serum separately, two cases of IgM (-) and IgG ( +) using serum and whole blood. The protein fingerprinting results and nucleic acid tests of 2019-nCoV antibodies were negative in the 4 cases. Considering the epidemiological history, clinical manifestations, and test results, these 4 children were ruled out for 2019-nCoV infection.

conclusionsWhen the colloidal gold method was used to detect 2019-nCoV-specific IgM/IgG antibodies, it was important to ascertain the test results as precisely as possible. Specimen type and patient history may interfere with the diagnosis.

Indexed as

COVID-19Nucleic AcidsChildCOVID-19 TestingGold ColloidHumansImmunoglobulin GImmunoglobulin MSARS-CoV-2Gold ColloidImmunoglobulin GImmunoglobulin MNucleic AcidsColloidal gold antibody detection methodFalse-positiveMass spectrometryNovel coronavirus infection

Identifiers

PMID35765042
PMCPMC9237983
OpenAlexW4283642991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.